Open Research will be unavailable from 10.15am - 11am on Saturday 14th March 2026 AEDT due to scheduled maintenance.
 

Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study

dc.contributor.authorNair-Shalliker, Visalini
dc.contributor.authorBang, Albert
dc.contributor.authorEgger, Sam
dc.contributor.authorYu, Xue
dc.contributor.authorChiam, Karen
dc.contributor.authorSteinberg, Julia
dc.contributor.authorPatel, Manish I.
dc.contributor.authorBanks, Emily
dc.contributor.authorO'Connell, Dianne L
dc.contributor.authorArmstrong, Bruce K
dc.contributor.authorSmith, David P
dc.date.accessioned2025-03-18T00:28:50Z
dc.date.available2025-03-18T00:28:50Z
dc.date.issued2022
dc.date.updated2023-12-24T07:15:48Z
dc.description.abstractBackground Prostate cancer (PC) aetiology is unclear. PC risk was examined in relation to several factors in a large population-based prospective study. Methods Male participants were from Sax Institute’s 45 and Up Study (Australia) recruited between 2006 and 2009. Questionnaire and linked administrative health data from the Centre for Health Record Linkage and Services Australia were used to identify incident PC, healthcare utilisations, Prostate Specific Antigen (PSA) testing reimbursements and dispensing of metformin and benign prostatic hyperplasia (BPH) prescriptions. Multivariable Cox and Joint Cox regression analyses were used to examine associations by cancer spread, adjusting for various confounders. Results Of 107,706 eligible men, 4257 developed incident PC up to end 2013. Risk of PC diagnosis increased with: PC family history (versus no family history of cancer; HRadjusted = 1.36; 95% CI:1.21–1.52); father and brother(s) diagnosed with PC (versus cancer-free family history; HRadjusted = 2.20; 95% CI:1.61–2.99); severe lower-urinary-tract symptoms (versus mild; HRadjusted = 1.77; 95% CI:1.53–2.04) and vasectomy (versus none; HRadjusted = 1.08; 95% CI:1.00–1.16). PC risk decreased with dispensed prescriptions (versus none) for BPH (HRadjusted = 0.76; 95% CI:0.69–0.85) and metformin (HRadjusted = 0.57; 95% CI:0.48–0.68). Advanced PC risk increased with vasectomy (HRadjusted = 1.28; 95% CI:1.06–1.55) and being obese (versus normal weight; HRadjusted = 1.31; 95% CI:1.01–1.69). Conclusion Vasectomy and obesity are associated with an increased risk of advanced PC. The reduced risk of localised and advanced PC associated with BPH, and diabetes prescriptions warrants investigation.
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0007-0920
dc.identifier.urihttps://hdl.handle.net/1885/733740475
dc.language.isoen_AUen_AU
dc.provenanceThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
dc.publisherNature Publishing Group
dc.relationhttp://purl.org/au-research/grants/nhmrc/1136128
dc.rights©2022 The authors
dc.rights.licenseCreative Commons Attribution licence
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceBritish Journal of Cancer
dc.titleFamily history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study
dc.typeJournal article
dcterms.accessRightsOpen Access
local.bibliographicCitation.issue4
local.bibliographicCitation.lastpage746
local.bibliographicCitation.startpage735
local.contributor.affiliationNair-Shalliker, Visalini, Cancer Council NSW
local.contributor.affiliationBang, Albert, Cancer Council NSW
local.contributor.affiliationEgger, Sam, Cancer Council NSW
local.contributor.affiliationYu, Xue, Cancer Council NSW
local.contributor.affiliationChiam, Karen, Cancer Research Division, Cancer Council NSW, Woolloomooloo, NSW, Australia
local.contributor.affiliationSteinberg, Julia, Cancer Council NSW
local.contributor.affiliationPatel, Manish I., Department of Urology, Westmead Hospital
local.contributor.affiliationBanks, Emily, College of Health and Medicine, ANU
local.contributor.affiliationO'Connell, Dianne L, Cancer Council NSW
local.contributor.affiliationArmstrong, Bruce K , School of Public Health, The University of Western Australia, Perth, Western Australia
local.contributor.affiliationSmith, David P, Cancer Council NSW
local.contributor.authoruidBanks, Emily, u4106314
local.description.notesImported from ARIES
local.identifier.absfor321109 - Predictive and prognostic markers
local.identifier.ariespublicationa383154xPUB36024
local.identifier.citationvolume127
local.identifier.doi10.1038/s41416-022-01827-1
local.identifier.scopusID2-s2.0-85130702865
local.publisher.urlhttps://www.nature.com/
local.type.statusPublished Version
publicationvolume.volumeNumber127

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s41416-022-01827-1.pdf
Size:
774.79 KB
Format:
Adobe Portable Document Format